bar for success for pbt2 in hd is very low, page-10

It seems to me there is a huge difference between HD and AD - please correct me if I'm wrong.

HD is caused by a single defective gene.If you have the gene you get HD. If you have HD, deterioration and death are inevitable.

It is hard to imagine a single drug like PBT2 stopping HD in it's tracks. Any cure or functional cure is likely to be gene-based and a long way off. PBT2 and similar drugs may be able to slow disease progress - a worthy objective ( and a way to fast track FDA approval).

AD is more complex. There are a number of genes that create a predisposition, plus various other unknown factors, such as environmental, possible exposure to viruses etc. No one knows.

It is far more likely that a drug like PBT2, or a cocktail of drugs, can interrupt the complex cascade of biochemical events involved in AD than in HD.That is, stop and even partially reverse the disease.

I think the results of the HD trial are encouraging for AD. I am holding for the AD results, and may pick up more.

Good luck to all longs